{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:00:54Z","timestamp":1787068854758,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,5,15]],"date-time":"2009-05-15T00:00:00Z","timestamp":1242345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s00404-009-1112-2","type":"journal-article","created":{"date-parts":[[2009,5,14]],"date-time":"2009-05-14T04:39:19Z","timestamp":1242275959000},"page":"221-227","source":"Crossref","is-referenced-by-count":56,"title":["Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy"],"prefix":"10.1007","volume":"281","author":[{"given":"Christof","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Weber-Schoendorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,5,15]]},"reference":[{"key":"1112_CR1","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1371\/journal.pmed.0030483","volume":"3","author":"L Abroms","year":"2006","unstructured":"Abroms L, Maibach E, Lyon-Daniel K, Feldman SR (2006) What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 3:e483. doi: 10.1371\/journal.pmed.0030483","journal-title":"PLoS Med"},{"key":"1112_CR2","first-page":"344","volume":"70","author":"J Adams","year":"2004","unstructured":"Adams J (2004) The adverse effect profile of neurobehavioral teratogens: retinoic acid. Birth Defects Res A 70:344","journal-title":"Birth Defects Res A"},{"key":"1112_CR3","first-page":"159","volume-title":"Functional neuroteratology of short term exposure to drugs","author":"J Adams","year":"1991","unstructured":"Adams J, Lammer E (1991) Relationship between dysmorphology and neuropsychological functions in children exposed to isotretinoin (in utero). In: Fujii T, Boer GJ (eds) Functional neuroteratology of short term exposure to drugs. Teiko University Press, Tokyo, pp 159\u2013168"},{"key":"1112_CR4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00228-006-0151-x","volume":"62","author":"L Azoulay","year":"2006","unstructured":"Azoulay L, Oraichi D, B\u00e9rard A (2006) Patterns and utilization of isotretinoin from 1984 to 2003: is there need for concern? Eur J Clin Pharmacol 62:667\u2013674. doi: 10.1007\/s00228-006-0151-x","journal-title":"Eur J Clin Pharmacol"},{"key":"1112_CR5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2125.2006.02837.x","volume":"63","author":"A B\u00e9rard","year":"2007","unstructured":"B\u00e9rard A, Azoulay L, Koren G et al (2007) Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 63:196\u2013205. doi: 10.1111\/j.1365-2125.2006.02837.x","journal-title":"Br J Clin Pharmacol"},{"key":"1112_CR6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0190-9622(92)70088-W","volume":"26","author":"WS Dai","year":"1992","unstructured":"Dai WS, LaBraico JM, Stern RS (1992) Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 26:599\u2013606. doi: 10.1016\/0190-9622(92)70088-W","journal-title":"J Am Acad Dermatol"},{"key":"1112_CR7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00404-006-0182-7","volume":"274","author":"M David","year":"2006","unstructured":"David M, Pachaly J, Vetter K (2006) Perinatal outcome in Berlin (Germany) among immigrants from Turkey. Arch Gynecol Obstet 274:271\u2013278. doi: 10.1007\/s00404-006-0182-7","journal-title":"Arch Gynecol Obstet"},{"key":"1112_CR8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.reprotox.2007.10.005","volume":"25","author":"F Garcia-Bournissen","year":"2008","unstructured":"Garcia-Bournissen F, Tsur L, Goldstein LH, Staroselsky A, Avner M, Asrar F, Berkovitch M, Straface G, Koren G, De Santis M (2008) Fetal exposure to isotretinoin\u2014an international problem. Reprod Toxicol 25:124\u2013128. doi: 10.1016\/j.reprotox.2007.10.005","journal-title":"Reprod Toxicol"},{"key":"1112_CR9","first-page":"79","volume":"64","author":"LB Holmes","year":"1999","unstructured":"Holmes LB (1999) Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology 64:79\u201382","journal-title":"Teratology"},{"key":"1112_CR10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/tera.1057","volume":"64","author":"MA Honein","year":"2001","unstructured":"Honein MA, Paulozzi LJ, Erickson JD (2001) Continued occurence of accutane exposed pregnancies. Teratology 64:142\u2013147. doi: 10.1002\/tera.1057","journal-title":"Teratology"},{"key":"1112_CR11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/tera.1048","volume":"64","author":"KA Johnson","year":"2001","unstructured":"Johnson KA, Weber PA, Jones KL et al (2001) Selection bias in teratology information service pregnancy outcome studies. Teratology 64:79\u201382. doi: 10.1002\/tera.1048","journal-title":"Teratology"},{"key":"1112_CR12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJM198510033131401","volume":"313","author":"EJ Lammer","year":"1985","unstructured":"Lammer EJ, Chen DT, Hoar RM et al (1985) Retinoic acid embryopathy. N Engl J Med 313:837\u2013841","journal-title":"N Engl J Med"},{"key":"1112_CR13","first-page":"A 58","volume":"43","author":"EJ Lammer","year":"1988","unstructured":"Lammer EJ, Hayes AM, Schunior A et al (1988) Unusually high risk for adverse outcomes of pregnancy following fetal isotretinoin exposure. Am J Hum Genet 43:A 58","journal-title":"Am J Hum Genet"},{"key":"1112_CR14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/(SICI)1096-9926(199908)60:2<54::AID-TERA3>3.0.CO;2-3","volume":"60","author":"ML Martinez-Frias","year":"1999","unstructured":"Martinez-Frias ML, Rodriguez-Pinilla E (1999) The problems of using data from teratology information services (TIS) to identify putative teratogens. Teratology 60:54\u201355. doi: 10.1002\/(SICI)1096-9926(199908)60:2<54::AID-TERA3>3.0.CO;2-3","journal-title":"Teratology"},{"key":"1112_CR15","doi-asserted-by":"crossref","first-page":"211A","DOI":"10.1002\/ajmg.a.20249","volume":"123","author":"JHM Merks","year":"2003","unstructured":"Merks JHM, van Karnebeek CDM, Caron HN, Hennekam RCM (2003) Phenotypic abnormalities: terminology and classification. Am J Med Genet 123:211A\u2013230A. doi: 10.1002\/ajmg.a.20249","journal-title":"Am J Med Genet"},{"key":"1112_CR16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10024-001-0258-0","volume":"5","author":"S Moerike","year":"2002","unstructured":"Moerike S, Pantzar JT, De Sa D (2002) Temporal bone pathology in fetuses exposed to isotretinoin. Pediatr Dev Pathol 5:405\u2013409. doi: 10.1007\/s10024-001-0258-0","journal-title":"Pediatr Dev Pathol"},{"key":"1112_CR17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1086\/JCE199708307","volume":"8","author":"JC Moskop","year":"1997","unstructured":"Moskop JC, Smith ML, De Ville K (1997) Ethical aspects of teratogenic medications: the case of isotretinoin. J Clin Ethics 8:264\u2013278","journal-title":"J Clin Ethics"},{"key":"1112_CR18","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/j.1552-4604.1998.tb04388.x","volume":"38","author":"I Nulman","year":"1998","unstructured":"Nulman I, Berkovitch M, Klein J et al (1998) Steady-state pharmacokinetics of isotretinoin and ist 4-oxo metabolite: implications for fetal safety. J Clin Pharmacol 38:926\u2013930","journal-title":"J Clin Pharmacol"},{"key":"1112_CR19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/(SICI)1096-9926(200005)61:5<327::AID-TERA2>3.0.CO;2-H","volume":"61","author":"A Ornoy","year":"2000","unstructured":"Ornoy A, Mastroiacovo P (2000) More on data from teratogen information systems (TIS). Teratology 61:327\u2013328. doi: 10.1002\/(SICI)1096-9926(200005)61:5<327::AID-TERA2>3.0.CO;2-H","journal-title":"Teratology"},{"key":"1112_CR20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/1471-2458-7-268","volume":"7","author":"K Raatikainen","year":"2007","unstructured":"Raatikainen K, Heiskanen N, Heinonen S (2007) Under-attending free antenatal care is associated with adverse pregnancy outcomes. BMC Public Health 7:268. doi: 10.1186\/1471-2458-7-268","journal-title":"BMC Public Health"},{"key":"1112_CR21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/bdra.10012","volume":"67","author":"SA Rasmussen","year":"2003","unstructured":"Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA (2003) Guidelines for case classification for the national birth defects prevention study. Birth Defects Res A 67:193\u2013201. doi: 10.1002\/bdra.10012","journal-title":"Birth Defects Res A"},{"key":"1112_CR22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/bdra.20197","volume":"73","author":"J Robertson","year":"2005","unstructured":"Robertson J, Polifka JE, Avner M et al (2005) A survey of pregnant women using isotretinoin. Birth Def Res A 73:881\u2013887. doi: 10.1002\/bdra.20197","journal-title":"Birth Def Res A"},{"key":"1112_CR23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0140-6736(83)90538-X","volume":"2","author":"FW Rosa","year":"1983","unstructured":"Rosa FW (1983) Teratogenicity of isotretinoin. Lancet 2:513. doi: 10.1016\/S0140-6736(83)90538-X","journal-title":"Lancet"},{"key":"1112_CR24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.reprotox.2008.05.064","volume":"26","author":"C Schaefer","year":"2008","unstructured":"Schaefer C, Arnoy A, Clementi M, Meister R, Weber-Schoendorfer C (2008) Using observational cohort data for studying drug effects on pregnancy outcome\u2014methodological considerations. Reprod Toxicol 26:36\u201341. doi: 10.1016\/j.reprotox.2008.05.064","journal-title":"Reprod Toxicol"},{"key":"1112_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/tera.1420440102","volume":"44","author":"Teratology Society","year":"1991","unstructured":"Teratology Society (1991) Recommendations for isotretinoin use in women of child-bearing potential. Teratology 44:1\u20136. doi: 10.1002\/tera.1420440102","journal-title":"Teratology"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-009-1112-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-009-1112-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-009-1112-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T05:55:37Z","timestamp":1710309337000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-009-1112-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,15]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1007\/s00404-009-1112-2","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,15]]}}}